On July 6, 2021, Agilent Technologies (NYSE: A) announced a strategic collaboration with GenomiCare Biotechnology in a move aimed to advance the application of the latest Next Generation Sequencing (NGS) technology into the clinical and scientific arena. More specifically, the purpose of using advanced NGS technology was to accelerate the process of development of genetic testing and related products and services, and to bring high level of clinical diagnosis and treatment of cancer in China.

Agilent is committed to working with industry leaders in China to help address the challenges in the rapidly growing field of NGS cancer diagnostics. Agilent has customized products that perform excellent in capturing and detecting symptoms, which provides the flexibility of application.

As an oncology medical service platform, GenomiCare Biotechnology focuses on providing precision treatment including program screening, implementation and monitoring. By analyzing the comprehensive clinical data of Chinese cancer patients, this high-tech corporation has carried out long-term scientific research cooperation with oncologists from many top hospitals in China and has achieved remarkable results.

As the key of this collaboration, GenomiCare Biotechnology will further optimize a number of oncology genetic testing products that based on Agilent's technology, including oncology targeting drug NGS testing, immunotherapy testing, gene oncology testing and solid tumor-related gene NGS testing.

In the future, the two companies will continue to work in depth with hospitals and oncologists on clinical research projects with a great contribution to the education and training of clinicians.